Suppr超能文献

L-抗坏血酸:真的是 HIF 脯氨酰羟化酶的底物吗?

L-ascorbic acid: A true substrate for HIF prolyl hydroxylase?

机构信息

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, 117997, Moscow, Russian Federation.

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, 117997, Moscow, Russian Federation.

出版信息

Biochimie. 2018 Apr;147:46-54. doi: 10.1016/j.biochi.2017.12.011. Epub 2017 Dec 28.

Abstract

L-Ascorbate (L-Asc), but not D-isoascorbate (D-Asc) and N-acetylcysteine (NAC) suppress HIF1 ODD-luc reporter activation induced by various inhibitors of HIF prolyl hydroxylase (PHD). The efficiency of suppression by L-Asc was sensitive to the nature of HIF PHD inhibitor chosen for reporter activation. In particular, the inhibitors developed to compete with alpha-ketoglutarate (αKG), were less sensitive to suppression by the physiological range of L-Asc (40-100 μM) than those having a strong iron chelation motif. Challenging those HIF activators in the reporter system with D-Asc demonstrated that the D-isomer, despite exhibiting the same reducing potency with respect to ferric iron, had almost no effect compared to L-Asc. Similarly, no effect on reporter activation was observed with cell-permeable reducing agent NAC up to 1 mM. Docking of L-Asc and D-Asc acid into the HIF PHD2 crystal structure showed interference of Tyr310 with respect to D-Asc. This suggests that L-Asc is not merely a reducing agent preventing enzyme inactivation. Rather, the overall results identify L-Asc as a co-substrate of HIF PHD that may compete for the binding site of αKG in the enzyme active center. This conclusion is in agreement with the results obtained recently in cell-based systems for TET enzymes and jumonji histone demethylases, where L-Asc has been proposed to act as a co-substrate and not as a reducing agent preventing enzyme inactivation.

摘要

L-抗坏血酸(L-Asc),而不是 D-异抗坏血酸(D-Asc)和 N-乙酰半胱氨酸(NAC),可抑制各种脯氨酰羟化酶(PHD)抑制剂诱导的 HIF1 ODD-luc 报告基因激活。L-Asc 的抑制效率对所选报告基因激活的 HIF PHD 抑制剂的性质敏感。特别是,与α-酮戊二酸(αKG)竞争的抑制剂,对生理范围内的 L-Asc(40-100μM)的抑制作用不如具有强铁螯合基序的抑制剂敏感。在报告基因系统中用 D-Asc 挑战那些 HIF 激活剂表明,尽管 D-异构体在还原高铁方面表现出相同的效力,但与 L-Asc 相比几乎没有效果。同样,细胞通透性还原剂 NAC 即使高达 1mM,也没有观察到对报告基因激活的影响。将 L-Asc 和 D-Asc 酸对接进入 HIF PHD2 晶体结构表明,D-Asc 对 Tyr310 存在干扰。这表明 L-Asc 不仅仅是一种还原剂,可防止酶失活。相反,总体结果表明 L-Asc 是 HIF PHD 的共底物,可能与酶活性中心的 αKG 结合位点竞争。这一结论与最近在基于细胞的 TET 酶和 jumonji 组蛋白去甲基酶系统中获得的结果一致,其中提出 L-Asc 作为共底物而不是还原剂,可防止酶失活。

相似文献

1
3
Structural Basis of Prolyl Hydroxylase Domain Inhibition by Molidustat.莫立司他抑制脯氨酰羟化酶结构基础。
ChemMedChem. 2021 Jul 6;16(13):2082-2088. doi: 10.1002/cmdc.202100133. Epub 2021 Apr 9.

引用本文的文献

7
Structure and Function of TET Enzymes.TET 酶的结构与功能。
Adv Exp Med Biol. 2022;1389:239-267. doi: 10.1007/978-3-031-11454-0_10.
8
High-Dose Vitamin C for Cancer Therapy.大剂量维生素C用于癌症治疗
Pharmaceuticals (Basel). 2022 Jun 3;15(6):711. doi: 10.3390/ph15060711.

本文引用的文献

4
Regulation of the Epigenome by Vitamin C.维生素C对表观基因组的调控
Annu Rev Nutr. 2015;35:545-64. doi: 10.1146/annurev-nutr-071714-034228. Epub 2015 May 6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验